|Day's Range||1.2000 - 1.2500|
Rewards that the next bull market will bring are being built right now by farsighted investors who can find opportunities among today's discounted stocks. While there's no telling exactly when a bull market will develop, planting the seeds of success by buying some shares of cheap yet high-quality companies out there right now is a good move. With that in mind, here are two businesses you're probably acquainted with that are priced for a no-brainer purchase -- and have a good shot at flourishing in the next bull market and beyond.
On that note, Pfizer (NYSE: PFE) has a habit of making its investors wealthier via its dividends and share repurchasing activity, and there's no reason to suspect that'll change through at least 2030. If you invested $5,000 in Pfizer a decade ago, right now you'd be happy to see that its total return in that period was around $10,900. In the next 10 years, there's no guarantee that it'll repeat that exact performance, but there are reasons to believe that it'll still be a good stock to own for the purposes of collecting its dividend and perhaps also experiencing share price appreciation over the long run.
UBS (NYSE:UBS) has offered to buy Credit Suisse (NYSE:CS) for up to $1B in an all-share deal, with the Swiss government planning to change laws to bypass a shareholder vote on the deal, according to a Financial Times report today. The proposed deal is set to be signed as soon as Sunday evening at a fraction of Credit Suisse's closing price on Friday. This week alone, Credit Suisse's shares have dropped more than 24% amid a series of scandals that have led to a decline in investor and client confidence, forcing the company to obtain $54B in central bank funding.